newsfilter
← Latest News
PR Newswire·

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

LONDON, May 20, 2022 /PRNewswire/ -- LumiraDx Limited (NASDAQ:LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use List